The European Commission granted approval for von Hippel-Lindau-associated renal cell carcinoma, CNS hemangioblastomas, or pancreatic neuroendocrine tumors.

In a Phase III trial, 28 percent of newly diagnosed patients with H3 K27M-mutant diffuse glioma responded to treatment with dordaviprone.

The firm is seeking accelerated approval for UX111 using reductions in levels of heparan sulfate in cerebrospinal fluid as a surrogate endpoint.

Researchers will launch a randomized clinical trial to assess whether PGx-guided care helps keep patients out of the ER and ...

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the ...

NEW YORK – The BC Cancer Foundation in Vancouver, British Columbia, said it aims to raise C$6.8 million (US$4.8 million) to expand its immunotherapy research program, which is focused on developing ...

NEW YORK – Aptose Biosciences on Thursday said it has entered into a common share purchase agreement with an institutional investor, which it expects will bring in around $2.1 million in gross ...

NEW YORK – Restore Vision on Thursday said it has treated the first patient in a Phase I/II trial with RV-001, the company's lead gene therapy that it is developing for retinitis pigmentosa (RP). The ...